Development and validation of a salivary tau biomarker in Alzheimer's disease

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring - Tập 11 - Trang 53-60 - 2018
Heather Pekeles1,2, Hamid Y. Qureshi2, Hemant K. Paudel1,2, Hyman M. Schipper1,2,3, Mervyn Gornistky1,2,3, Howard Chertkow1,2,3,4
1Departments of Neurology and Neurosurgery and Dentistry, McGill University, Montreal, Québec, Canada
2Lady Davis Institute, Montreal, Québec, Canada
3Jewish General Hospital, Montreal, Québec, Canada
4Baycrest Health Sciences, Toronto, Ontario, Canada

Tóm tắt

AbstractIntroductionTotal tau (t‐tau) and phosphorylated tau (p‐tau) are abnormally elevated in the brain and cerebrospinal fluid of individuals with Alzheimer's disease (AD). Tau is also present in the salivary gland tissue and saliva, and salivary measures might produce an accurate, accessible, and inexpensive biomarker.MethodsUsing unstimulated saliva and Western blot analysis, we quantified the p‐tau/t‐tau ratio at different phosphorylation sites.ResultsWe found that for one phosphorylation site, S396, p‐tau/t‐tau ratio was significantly elevated in patients with AD compared with normal elderly control subjects. The elevation in saliva, however, did not correlate with cerebrospinal fluid tau or with brain measures such as hippocampal volume.DiscussionThere is significant elevation of p‐tau/t‐tau ratio for the S396 phosphorylation site. Large variation in the AD salivary tau levels, however, limits the utility of this test as a clinical biomarker.

Tài liệu tham khảo

10.1016/S0197-4580(98)00023-2 10.1016/j.mcna.2012.12.012 10.1385/MN:24:1-3:087 10.1016/j.cca.2015.01.041 10.1602/neurorx.1.2.213 10.3233/JAD-2011-110731 10.1016/j.freeradbiomed.2015.04.005 10.1016/j.jalz.2015.06.608 10.1186/alzrt198 10.1016/j.jalz.2011.03.008 10.1001/archneur.56.3.303 10.1016/S0140-6736(15)00461-4 10.1016/j.neurobiolaging.2011.02.022 10.1002/hbm.22390 10.1017/S1355617715000776 10.1016/j.neuropsychologia.2015.09.024 10.1016/j.jalz.2011.03.005 Rascuvsky K., 2011, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 2456, 10.1093/brain/awr179 10.1111/j.1532-5415.2005.53221.x 10.1016/j.jalz.2012.10.001 10.1016/j.jalz.2012.09.017 10.1016/S0304-3940(00)01697-9 Wechsler D., 1997, Whechsler Memory Scale ‐ Third Edition, Adminitration and Scoring Manual 10.1037/0735-7028.22.6.510 10.1080/09084282.2013.780172 10.1002/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U 10.1159/000203344 10.1007/s11682-010-9088-x 10.1001/archneur.1994.00540210060013 10.1001/archneur.56.6.713 10.1101/cshperspect.a006189 10.1097/00005072-199904000-00008 10.1159/000077170 10.1016/j.jalz.2014.12.006 10.1016/j.jalz.2015.01.001 10.1001/jamaneurol.2015.0202 10.1007/BF00308809 Visser P., 2002, Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment, J Neurol Neurosurg Psychiatr, 72, 491 10.1016/j.neuroimage.2008.07.022 10.1159/000007969 10.1073/pnas.112194599 Francois M., 2014, Biomarkers of Alzheimer's disease risk in peripheral tissues; focus on buccal cells, Curr Alzheimer Res, 11, 519, 10.2174/1567205011666140618103827
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Tập 11

53-60

Thông tin tác giả